Product Description
for the Treatment of ALpha-1 ANTitrypsin Deficiency. Alvelestat (MPH966, formerly AZD9668) is a potent, selective, and reversible, oral inhibitor of human NE. Suppression of NE is expected to reduce lung damage and may slow disease progression. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03679598)
Mechanisms of Action: ELA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Orphan Drug - alpha 1-Antitrypsin Deficiency *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, Denmark, Poland, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: COVID-19|Chronic Obstructive Pulmonary Disease|Emphysema|alpha 1-Antitrypsin Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATALANTa | P2 |
Completed |
Emphysema|alpha 1-Antitrypsin Deficiency|Chronic Obstructive Pulmonary Disease |
2023-11-30 |
|
| ASTRAEUS | P2 |
Completed |
Emphysema|alpha 1-Antitrypsin Deficiency|Chronic Obstructive Pulmonary Disease |
2022-03-02 |
|
| COSTA | P2 |
Completed |
COVID-19 |
2021-10-29 |